Results 231 to 240 of about 54,679 (264)

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

Journal of Clinical Oncology
PURPOSE Neoadjuvant immune checkpoint blockade with nivolumab plus ipilimumab improves overall survival (OS) in non–small cell lung cancer (NSCLC); however, randomized data for resectable lung cancer are limited.
M. Awad, P. Forde, Nicolas Girard, J. Spicer, Changli Wang, Shun Lu, Tetsuya Mitsudomi, E. Felip, Stephen R Broderick, Scott J. Swanson, J. Brahmer, Keith Kerr, G. Saylors, Ke-Neng Chen, V. Gharpure, J. Neely, D. Balli, N. Hu, Mariano Provencio Pulla   +18 more
semanticscholar   +1 more source

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA

ESMO Open
Background The phase III CheckMate 9LA study demonstrated durable overall survival (OS) benefit with nivolumab plus ipilimumab with chemotherapy versus chemotherapy in patients with metastatic non-small-cell lung cancer (NSCLC).
D. Carbone, T. Ciuleanu, M. Cobo, M. Schenker, B. Zurawski, J. Menezes, E. Richardet, E. Felip, Y. Cheng, O. Juan-Vidal, A. Alexandru, H. Mizutani, N. Reinmuth, S. Lu, M. Reck, T. John, A. Scherpereel, P. de Marchi, T. Aoyama, P. Sathyanarayana, D. Grootendorst, N. Hu, V. Ip, Y.-H. Hung, L. Paz-Ares   +24 more
semanticscholar   +1 more source

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

Annals of Oncology
BACKGROUND Pembrolizumab significantly improved overall survival (OS) versus ipilimumab for unresectable advanced melanoma in KEYNOTE-006 (NCT01866319); 10-year follow-up data are presented.
G. V. Long, M. Carlino, C. McNeil, A. Ribas, C. Gaudy-Marqueste, J. Schachter, M. Nyakas, D. Kee, T. Petrella, A. Blaustein, M. Lotem, A. Arance, A. Daud, O. Hamid, J. Larkin, L. Yao, R. Singh, R. Lal, C. Robert   +18 more
semanticscholar   +1 more source

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.

The Lancet Oncology, 2020
BACKGROUND Previously, findings from CheckMate 238, a double-blind, phase 3 adjuvant trial in patients with resected stage IIIB-C or stage IV melanoma, showed significant improvements in recurrence-free survival and distant metastasis-free survival with ...
P. Ascierto, M. Del Vecchio, M. Mandalà, H. Gogas, A. Arance, S. Dalle, C. Cowey, M. Schenker, J. Grob, V. Chiarion-Sileni, I. Márquez-Rodas, M. Butler, M. Maio, M. Middleton, L. de la Cruz-Merino, P. Arenberger, V. Atkinson, A. Hill, L. Fecher, M. Millward, N. Khushalani, P. Queirolo, M. Lobo, V. de Pril, J. Loffredo, J. Larkin, J. Weber   +26 more
semanticscholar   +1 more source

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

The Lancet Oncology, 2018
BACKGROUND Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ...
F. Hodi, V. Chiarion-Sileni, R. Gonzalez, J. Grob, P. Rutkowski, C. Cowey, C. Lao, D. Schadendorf, J. Wagstaff, R. Dummer, P. Ferrucci, M. Smylie, A. Hill, D. Hogg, I. Márquez-Rodas, Joel Jiang, J. Rizzo, J. Larkin, J. Wolchok   +18 more
semanticscholar   +1 more source

Ipilimumab

Reactions Weekly, 2013
  +6 more sources

Ipilimumab/ipilimumab/nivolumab

Reactions Weekly, 2022
openaire   +1 more source

Ipilimumab

Reactions Weekly, 2022
openaire   +1 more source

Ipilimumab

Reactions Weekly, 2016
  +4 more sources

Ipilimumab

Reactions Weekly, 2014
  +4 more sources